Setmelanotide (Imcivree): MC4R Evidence, FDA Label and Safety Limits
Setmelanotide guide covering the Imcivree label, MC4R rare-obesity evidence, acquired hypothalamic obesity approval and safety limits.
Setmelanotide is different from the weight-loss peptides most people search for first. It is not semaglutide, tirzepatide, retatrutide or an amylin-pathway drug such as cagrilintide. It is a melanocortin-4 receptor agonist, usually shortened to MC4R agonist, sold under the brand Imcivree.
The label is narrow and important. DailyMed's April 2026 Imcivree label lists setmelanotide for reducing excess body weight and maintaining weight reduction long term in specific rare obesity settings: acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older, Bardet-Biedl syndrome in patients aged 2 years and older, and obesity due to POMC, PCSK1 or LEPR deficiency in patients aged 2 years and older when label criteria are met.
That does not make setmelanotide a general obesity shot. The same label states that Imcivree is not indicated for other obesity types, including general polygenic obesity. For broad comparisons, use peptides for weight loss, GLP-1 for weight loss, and the weight-loss peptide database category.
This guide is educational and not medical advice. Rare genetic obesity, acquired hypothalamic obesity, endocrine disease, pediatric obesity and medication choice require clinician evaluation. Setmelanotide is a prescription drug with label warnings, monitoring needs and use limits.
Setmelanotide At A Glance
| Question | Evidence-aware answer |
|---|---|
| Drug name | Setmelanotide. |
| Brand | Imcivree. |
| Drug class | Melanocortin-4 receptor agonist. |
| Main pathway | Central melanocortin signaling involved in hunger, satiety and energy balance. |
| Approved-use frame | Selected rare obesity indications, including acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC, PCSK1 or LEPR deficiency under label criteria. |
| Not a GLP-1 | It does not work through GLP-1 receptor agonism. |
| Main label warnings | Sexual adverse reactions, depression and suicidal ideation, hypersensitivity, skin hyperpigmentation, adrenal insufficiency and sodium imbalance concerns in acquired hypothalamic obesity. |
What Setmelanotide Does
The central melanocortin pathway helps regulate appetite and body weight. In simple terms, POMC neurons produce melanocortin signals that activate MC4R pathways downstream. LEPR signaling sits upstream of that system. PCSK1 is involved in processing prohormones such as POMC.
When this pathway is disrupted by rare genetic disease, hunger and early severe obesity can be biologically different from common obesity. Setmelanotide was developed to activate MC4R signaling downstream of certain pathway defects. That is why genetic diagnosis and clinical context are central to the label.
The same mechanism also explains why setmelanotide should not be compared only by percentage weight loss. It is designed for a narrow biology problem. That makes it more like a pathway-targeted orphan obesity drug than a direct rival to high-volume GLP-1 medicines covered in the FDA-approved GLP-1 guide.
What The FDA Label Covers
The April 2026 Imcivree label lists three approved indication groups. Acquired hypothalamic obesity is the newest important addition. It covers adults and pediatric patients aged 4 years and older with acquired HO. Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency are listed for patients aged 2 years and older.
The limitations of use are just as important as the indication. DailyMed says Imcivree is not indicated for obesity due to suspected POMC, PCSK1 or LEPR deficiency when variants are benign or likely benign, and not for obesity that is unrelated to acquired HO, BBS or POMC, PCSK1 or LEPR deficiency. That includes obesity associated with other genetic syndromes and general polygenic obesity.
| Label category | What it means for readers |
|---|---|
| Acquired hypothalamic obesity | A rare condition related to hypothalamic injury or impairment, not ordinary weight gain. |
| Bardet-Biedl syndrome | A syndromic obesity indication with clinical diagnosis and, in some pediatric contexts, genetic confirmation considered. |
| POMC, PCSK1 or LEPR deficiency | A monogenic pathway context where genetic interpretation matters. |
| General obesity | The label explicitly excludes general polygenic obesity. |
Human Evidence In POMC, PCSK1 And LEPR Deficiency
The pivotal POMC and LEPR evidence came from small, open-label, multicenter phase 3 trials with a placebo-controlled withdrawal period. The PubMed record for the Lancet Diabetes and Endocrinology report describes participants with severe obesity due to POMC or LEPR deficiency, treatment with setmelanotide, and clinically meaningful weight and hunger outcomes in a rare-disease sample.
The sample was small because the diseases are rare. That should not be read as a weakness in the same way as an underpowered consumer supplement study. Rare genetic disease trials often use different designs than mass-market obesity trials. Still, small sample size matters when judging precision, long-term safety and generalizability.
Quality-of-life analyses from the same trial program add useful context. They describe severe hunger, obesity burden and quality-of-life impairment in POMC and LEPR deficiency, with changes during setmelanotide treatment. Those data help explain why the drug exists, but they do not broaden the approved use.
Bardet-Biedl Syndrome Evidence
Bardet-Biedl syndrome, or BBS, is a rare multisystem genetic condition that can include early-onset obesity and hyperphagia. Setmelanotide was studied in BBS through phase 2 and phase 3 clinical work.
The phase 3 PubMed record describes a multicenter, randomized, double-blind, placebo-controlled trial with an open-label period in patients with Bardet-Biedl syndrome and Alstrom syndrome. The authors concluded that the results supported use in BBS and formed evidence for approval in that group.
The label distinction is precise. Imcivree is approved for BBS, but the label does not turn every syndromic obesity diagnosis into a setmelanotide indication. That matters for families searching after a new genetic diagnosis. The pathway, diagnosis and label criteria matter more than the broad phrase "genetic obesity."
Acquired Hypothalamic Obesity Evidence
Acquired hypothalamic obesity is different from inherited MC4R pathway disease. It can follow hypothalamic injury or impairment, including situations around brain tumors such as craniopharyngioma, treatment effects or other injury contexts. The clinical problem is often rapid, sustained weight gain and hyperphagia after hypothalamic damage.
In March 2026, Rhythm Pharmaceuticals announced FDA approval of an expanded Imcivree indication for acquired hypothalamic obesity. The updated DailyMed label now includes acquired HO and adds label warnings specific to that population, including acute adrenal insufficiency and sodium imbalance in patients with central diabetes insipidus.
The PubMed record for the phase 2 acquired HO study describes an open-label, multicenter trial. That is useful human evidence, but it is not the same as a large, long-term general obesity outcomes program. The right reading is narrow: setmelanotide has an approved acquired HO label, and the condition requires specialist care because hypothalamic injury can involve adrenal, sodium, pituitary and tumor-history issues.
Side Effects And Monitoring Issues
Setmelanotide's label warnings fit its biology. MC4R agonism is not only a weight pathway. DailyMed warns about disturbance in sexual arousal, including spontaneous penile erections in males and sexual adverse reactions in females. It also warns about depression and suicidal ideation, serious hypersensitivity, skin hyperpigmentation, darkening of existing nevi and development of new melanocytic nevi.
That skin-pigment signal connects setmelanotide with the wider melanocortin family, but it should not be confused with unapproved tanning peptides such as Melanotan II. A regulated MC4R drug for rare obesity and an unapproved tanning peptide are different evidence and safety objects.
Acquired HO adds extra monitoring context. The 2026 label includes warnings about acute adrenal insufficiency and sodium imbalance in patients with central diabetes insipidus. Those are not casual side effects. They belong to the endocrine complexity of hypothalamic disease.
How To Read Setmelanotide Claims
| Claim | Better question |
|---|---|
| "FDA-approved weight-loss peptide" | Approved for which rare indication and age group? |
| "Works through hunger control" | Is the hunger problem tied to BBS, acquired HO, POMC, PCSK1 or LEPR pathway disease? |
| "Alternative to GLP-1" | Is the reader discussing a label-eligible rare obesity condition or general obesity? |
| "MC4R means no GLP-1 side effects" | What does the Imcivree label say about pigment, mood, sexual, hypersensitivity and endocrine risks? |
| "Good for any genetic obesity" | Does the diagnosis match the label, or is it another syndrome or benign variant? |
Reddit, rare-disease forums and investor discussions show current demand because setmelanotide sits at the intersection of obesity medicine, genetics and a 2026 acquired HO label expansion. Those discussions can identify common questions. They cannot determine diagnosis, genetic interpretation or whether the drug is appropriate for a specific patient.
Where Setmelanotide Fits
Setmelanotide belongs in the weight-management map, but not in the same lane as ordinary GLP-1 selection. The usual GLP-1 questions ask about dose schedules, cost, access, side effects and comparative average weight loss. Setmelanotide questions start earlier: what is the diagnosis, what pathway is affected, what does the label allow, and which specialist is managing endocrine risk?
Compared with PT-141 bremelanotide, setmelanotide shares melanocortin-family biology but has a different receptor emphasis and a different approved use. Compared with retatrutide, it is not an investigational triple agonist. Compared with cagrilintide, it is not an amylin analog.
For handling and calculation concepts, PeptideStat has peptide half-life explained and peptide calculators. Those tools are educational. They do not replace a prescription label or rare-disease clinician judgment.
Bottom Line
Setmelanotide is a real FDA-approved peptide drug, but its value comes from a narrow label. It targets MC4R pathway biology in selected rare obesity conditions, including the acquired hypothalamic obesity indication added in 2026.
The key mistake is treating setmelanotide as a general weight-loss peptide. It is not a GLP-1, not an amylin analog and not a research-market shortcut. It is a prescription MC4R agonist for defined rare obesity contexts with label warnings that require medical oversight.
References
DailyMed. Imcivree setmelanotide injection prescribing information.
Clement K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency.
Haqq AM, et al. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alstrom syndrome.
Haws RM, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.
Roth CL, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Kuhnen P, et al. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
Krashes MJ, Lowell BB, Garfield AS. The melanocortin pathway and energy homeostasis: From discovery to obesity therapy.
NCBI Bookshelf LiverTox. Setmelanotide.
Rhythm Pharmaceuticals. FDA approval of Imcivree for patients with acquired hypothalamic obesity.